Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab

被引：0
|
作者：
Reck, Martin
Granados, Ana Laura Ortega
de Marinis, Filippo
Meyers, Oren
Boklage, Susan
Shen, Qin
Cho, Lillian
机构：
[1] Lungen Clin, Grosshansdorf, Germany
[2] Hosp Univ Jaen, Serv Oncol Med, Jaen, Spain
[3] European Inst Oncol, Milan, Italy
[4] GSK, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9099
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Patient-Reported Outcomes (PROs) in Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): PERLA Trial Comparing First-Line Chemotherapy Plus Dostarlimab or Pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Shen, Qin
    Cho, Lillian
    Boklage, Susan
    Gouldin, Winston
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E26 - E27
  • [2] Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Shen, Qin
    Cho, Lillian
    Stjepanovic, Neda
    Boklage, Susan
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [3] Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
    Lim, Sun Min
    Peters, Solange
    Granados, Ana Laura Ortega
    Pinto, Gustavo dix Junqueira
    Fuentes, Christian Sebastian
    Lo Russo, Giuseppe
    Schenker, Michael
    Ahn, Jin Seok
    Reck, Martin
    Szijgyarto, Zsolt
    Huseinovic, Neda
    Zografos, Eleftherios
    Buss, Elena
    Stjepanovic, Neda
    ODonnell, Sean
    de Marinis, Filippo
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [4] Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
    Sun Min Lim
    Solange Peters
    Ana Laura Ortega Granados
    Gustavo dix Junqueira Pinto
    Christian Sebastián Fuentes
    Giuseppe Lo Russo
    Michael Schenker
    Jin Seok Ahn
    Martin Reck
    Zsolt Szijgyarto
    Neda Huseinovic
    Eleftherios Zografos
    Elena Buss
    Neda Stjepanovic
    Sean O’Donnell
    Filippo de Marinis
    Nature Communications, 14
  • [5] Dostarlimab plus chemotherapy (CT) vs pembrolizumab plus CT in metastatic non-squamous non-small cell lung cancer (NSCLC): Updated Asian subgroup analyses of the PERLA trial
    Lee, D. H.
    Ahn, J. S.
    Lin, S-H.
    Ulanska, M.
    Lopez, G. A.
    Chian, C-F.
    Cho, L.
    Szijgyarto, Z.
    Stjepanovic, N.
    Lim, S. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1662 - S1663
  • [6] Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?
    Le, Laura
    van Dams, Ritchell
    Lee, Percy
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S327 - S330
  • [7] Dostarlimab (Dos) or pembrolizumab (Pem) plus chemotherapy (CT) in previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC): Patient (Pt) and disease characteristics subgroup analyses from the PERLA trial
    Granados, A. L. O. Ortega
    Lim, S. M.
    Schenker, M.
    De Marinis, F.
    Puig, J. M.
    Lee, D. H.
    Arriola, E.
    Pradera, J. Fuentes
    O'Donnell, S.
    Szijgyarto, Z.
    Cho, L.
    Ahn, J. S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S67 - S68
  • [8] Pharmacological Comparison of Dostarlimab and Pembrolizumab in Metastatic Non-Small Cell Lung Cancer in PERLA
    Samant, T. S.
    Struemper, H.
    Franzese, R. C.
    Goulooze, B.
    Muliaditan, M.
    Melhem, M.
    Ghosh, S.
    Fastenrath, M.
    Stjepanovic, N.
    Szijgyarto, Z.
    Rathi, C.
    Mantero, A.
    Hanafin, P.
    Zajic, S.
    Yanamandra, N.
    Chung, C-W.
    Vlahovic, G.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S407 - S408
  • [9] Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer
    Paladini, Luciano
    Pereira da Veiga, Cassia Rita
    Cerqueira, Erica
    Haas, Laura Chabrol
    Abadi, Marcia Datz
    Baldotto, Clarissa Serodio
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1185 - 1193
  • [10] Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).
    Kim, Ashley
    Devine, Beth
    Roth, Joshua A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345